BioSpace News Archive

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced that it has launched its new Aladdin-M instrument to the US market.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data are being presented in an oral presentation at The Digital Internat

Imbrium Therapeutics announced results from two Phase 1b studies evaluating the safety, tolerability and efficacy of IMB-115 in patients with insomnia disorder.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in September: T

The TARGIT Collaborative Group (TCG) is pleased to announce publication of the long-term results of the Targeted Intraoperative Radiotherapy Trial (TARGIT-A Trial) comparing partial breast single fraction targeted intraoperative radiotherapy (TARGIT-IORT) to 3-6 week post-operative whole breast radiotherapy, demonstrating equivalent long-term outcomes between the two treatments. The results of the trial were published

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the LD 500 Virtual Investor Conference on Friday, September 4 at 11 a.m. ET. Sanjay Subramanian, Chief Financial Officer, will present virtually to an online audience highlighting Ocugen’s breakthrough gene therapy platform as well as its

Golden State Dermatology is pleased to announce Kathy Fang, M.D., Ph.D. and her team have joined Golden State Dermatology.

Movano Inc., a health-focused technology company dedicated to enhancing the quality of life for people affected by chronic health conditions, including diabetes, has closed its bridge round at $12.5M.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it needs additional time to complete its review of TLANDO’s New Drug Application (“NDA”) and is committed to taking ac

Xeris Pharmaceuticals, Inc. announced that on August 26, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under Xeris’ Inducement Equity Plan.